LATAM Adalimumab Market

Latin America Adalimumab Market to Reach
US$1.18 bn by 2023; Rheumatoid Arthritis,
Psoriasis Represent Largest Application Segments
Rise in drug resistant species, launch of generics, and upcoming patent expirations during the
period of 2015 to 2023 is likely to hamper the growth of the global antibacterial drugs market,
states Transparency Market Research in its latest report. The 150-page research publication,
titled “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and
Forecast 2015 - 2023”, indicates that registering a poor CAGR of 1.30% during the forecast
period, the worldwide market for antibacterial drugs in projected to drop from US$43.9 Bn in
2014 to US$38.9 Bn by 2023.
Adalimumab is an anti-inflammatory medication usually prescribed for treating Crohn's disease,
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, moderate to
severe hidradenitis suppurativa, moderate to severe chronic psoriasis, and juvenile idiopathic
arthritis. The medication is known to be a TNF inhibitor and an anti-inflammatory medication. It
is popularly sold under the trade names of Humira and Exemptia as approved by the U.S. Food
and Drug Administration (FDA).
Though adalimumab was initially approved in the U.S., it is now being sold in over 60 countries.
Over the years, the technological advancements and increasing research and development
activities for developing biosimilars of adalimumab have created several growth opportunities
for these drugs. Furthermore, factors such as the improved diagnosis rate of diseases and a huge
support from efficient biological drugs will also propel the growth of the Latin America
adalimumab market.
A research report by Transparency Market Research suggests that the LATAM adalimumab
market was valued at US$994.8 mn in 2014 and is expected to register a CAGR of 0.4% between
2015 and 2023 to reach a value of US$1,186.4 mn by 2023. This growth will be attributable to
the growing preference for effective medications, low cost of production as patents reach their
expiry dates, improving marketing strategies, and abundant availability of medical expertise in
biosimilar research in Latin American countries.
The Latin America adalimumab market has been segmented on the basis of application and
country. The applications of adalimumab are seen in the treatment of diseases such as rheumatoid
arthritis, psoriasis, Crohn’s disease, ulcerative colitis, and others. In terms of countries, this
market is segmented into Argentina, Colombia, Brazil, and Rest of LATAM.

Browse Full Research Report on LATAM Adalimumab Market:
http://www.transparencymarketresearch.com/latam-adalimumab-market.html
The rheumatoid arthritis application segment held the biggest share in the Latin American
adalimumab market due to extensive research on the subject, increasing acceptance of
adalimumab for treating rheumatoid arthritis, and improving diagnosis of the health condition at
lab levels. A research paper published by Reumatologia Clinica Journal in 2013, titled ‘Current
Therapies in Rheumatoid Arthritis,’ shows that the use of TNF inhibitors such as adalimumab for
treating rheumatoid arthritis is extremely common.
The paper also highlights that the growing incidence of this disease will accelerate the usage of
adalimumab. The factors restraining the growth of the adalimumab market in Latin America are
the risks of infections and possible side effects posed by these medications. However, the
demand of adalimumab for treating psoriasis will offset this negative effect in the near future.
The Latin America adalimumab market will also be positively influenced by the growing
healthcare expenditure and growing preference for biologic drugs in the region. Some of the
important players operating in the Latin American adalimumab market are Boehringer Ingelheim
GmbH, Pfizer, Inc., AbbVie, Inc. Amgen, Inc., Mylan N.V., and Novartis AG.
In the current market scenario, the majority of the players are trying to develop adalimumab
biosimilars that will treat psoriasis and rheumatoid arthritis. The ongoing clinical trials for
ensuring the safety and efficacy of these biosimilars are a testimony to this fact. This R&D
avenue is expected to retain an important place in the adalimumab market in Latin America in
the coming years.
Browse Full Press Release on LATAM Adalimumab Market:
Press Release
About Us
Transparency Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight for thousands of decision
makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that
it always reflects the latest trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for business reports.

Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com